植物源重组保护性抗原(rPA)炭疽疫苗在健康成人中的安全性与免疫原性:一项1期剂量递增研究
该研究在18-49岁健康成人中评估植物源PA83-FhCMB炭疽疫苗(12.5、25、50或100 µg加Alhydrogel®佐剂)的安全性和免疫原性,受试者按28天间隔肌内接种三剂。四个剂量组均安全且具免疫原性,未观察到相关严重不良事件,最高剂量组抗体应答最强,第180天抗体应答在各剂量组均下降。
要点
- 四个剂量组(12.5、25、50、100 µg)均安全且具免疫原性,未观察到相关严重不良事件。
- ELISA GMC和TNA ED50 GMT峰值出现在第84天(末剂后1个月),最高剂量组应答最强。
- 第180天各剂量组抗体应答均下降,未收集超过6个月的长期免疫原性数据。
核心结论
- 这是首次在健康成人中证明植物源亚单位炭疽疫苗安全性和免疫原性的研究,结果支持对PA83-FhCMB疫苗开展进一步临床研究。
研究设计与样本
- 首次人体、单盲、1期剂量递增研究,在单中心开展,评估植物源PA83-FhCMB疫苗(加Alhydrogel®佐剂)在18-49岁(含)健康成人中的安全性、反应原性和免疫原性。
- 受试者在四个递增剂量水平(12.5、25、50或100 µg)接种,按28天间隔肌内接种三剂。
- 安全性在接种后第3、7、14天评估;免疫原性用酶联免疫吸附试验(ELISA)和毒素中和抗体(TNA)试验在第0、14、28、56、84和180天评估。
主要发现
- 四个剂量范围均安全且具免疫原性,未观察到相关严重不良事件。
- ELISA几何平均浓度(GMC)和TNA ED50几何平均滴度(GMT)峰值出现在第84天(末剂后1个月),最高剂量组检测到最强应答。
- 第180天时各剂量组抗体应答均下降。
局限性
- 未收集超过六个月的长期免疫原性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential use of Bacillus anthracis as a bioterrorism weapon requires a safe and effective vaccine that can be immediately distributed for mass vaccination. Protective antigen (PA), a principal component of virulence factors edema toxin and lethal toxin of B. anthracis, has been the topic of extensive research. Previously, full-length PA (PA83) was manufactured using a transient plant-based expression system. Immunization with this PA83 antigen formulated with Alhydrogel® adjuvant elicited strong neutralizing immune responses in mice and rabbits and protected 100% of rabbits from a lethal aerosolized B. anthracis challenge. This Phase 1 study evaluates this vaccine's safety and immunogenicity in healthy human volunteers. METHODS: This first-in-human, single-blind, Phase 1 study was performed at a single center to investigate the safety, reactogenicity, and immunogenicity of the plant-derived PA83-FhCMB vaccine at four escalating dose levels (12.5, 25, 50 or 100 µg) with Alhydrogel® in healthy adults 18-49 years of age (inclusive). Recipients received three doses of vaccine intramuscularly at 28-day intervals. Safety was evaluated on days 3, 7, and 14 following vaccination. Immunogenicity was assessed using an enzyme-linked immunosorbent assay (ELISA) and a toxin neutralizing antibody (TNA) assay on days 0, 14, 28, 56, 84, and 180. RESULTS: All four-dose ranges were safe and immunogenic, with no related serious adverse events observed. Peak ELISA Geometric Mean Concentration (GMC) and TNA ED50 Geometric Mean Titer (GMT) were noted at Day 84, 1 month after the final dose, with the most robust response detected in the highest dose group. Antibody responses decreased by Day 180 across all dose groups. Long-term immunogenicity data beyond six months was not collected. CONCLUSIONS: This is the first study demonstrating a plant-derived subunit anthrax vaccine's safety and immunogenicity in healthy adults. The results support further clinical investigation of the PA83-FhCMB vaccine. ClinicalTrials.gov identifier. NCT02239172.
引用
- Paolino KM, Regules JA, Moon JE, et al. Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults. Vaccine. 2022. PMID: 35153091. doi:10.1016/j.vaccine.2022.01.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。